Xiuning Le, MD, PhD, The University of Texas MD Anderson Cancer Centre, Houston, Texas, comments on the current status of antibody-drug conjugates (ADCs) in the treatment of lung cancer. The current goal in the lung cancer field is to understand the patient populations that will benefit from ADCs. Dr Le shares that a number of Phase I/II clinical trials have been initiated for ADCs in lung cancer, and some encouraging data will be released. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть